CUE — Cue Biopharma Balance Sheet
0.000.00%
- $59.16m
- $41.03m
- $9.29m
Annual balance sheet for Cue Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 84.9 | 64.4 | 76.3 | 48.5 | 22.5 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.42 | 3.14 | 0.057 | 1.7 | 0.945 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 87.5 | 68.5 | 77.2 | 51.5 | 25.1 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 8.88 | 11.9 | 10.7 | 7.12 | 4.84 |
Other Long Term Assets | |||||
Total Assets | 99.5 | 83.4 | 91.3 | 61.5 | 32.2 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 16.3 | 12.8 | 11.5 | 17.1 | 13.7 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 20.6 | 17.9 | 25.6 | 24.4 | 14.7 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 78.9 | 65.5 | 65.7 | 37.1 | 17.5 |
Total Liabilities & Shareholders' Equity | 99.5 | 83.4 | 91.3 | 61.5 | 32.2 |
Total Common Shares Outstanding |